Request Free Sample
×
South Korea Anti Hypertensive Drugs Market
ID: MRFR/HC/54822-HCR
200 Pages
June 2025
South Korea Antihypertensive Drugs Market South Korea Antihypertensive Drugs Market Research Report: By Drug Class (Diuretics, ACE Inhibitors, Beta Blockers, Calcium Channel Blockers, Angiotensin II Receptor Antagonists), By Administration Route (Oral, Injectable, Transdermal), By Indication (Essential Hypertension, Secondary Hypertension, Hypertensive Crisis) andBy Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)- Forecast to 2035
Industry Developments
Recent developments in the South Korea Antihypertensive Drugs Market include a commendable growth trajectory driven by an aging population and increasing prevalence of hypertension. In September 2023, Celltrion announced advancements in its hypertension treatment drugs, emphasizing Research and Development to cater to growing patient demands. CJ HealthCare has also expanded its portfolio, enhancing its offerings in hypertension management. Furthermore, in August 2023, Hanmi Pharmaceutical launched a new combination drug, gaining attention for its innovative approach to treating high blood pressure. Notably, in April 2023, Yuhan Corporation completed the acquisition of a small biotech firm, integrating new technologies into their hypertension drug development pipeline. The market remains robust as companies like LG Chem and Daewoong Pharmaceutical report significant increases in valuation attributed to their enhanced focus on antihypertensive medications and strategic marketing initiatives. Over the past two years, from early 2022, the market has seen investments directed toward creating more effective and accessible antihypertensive solutions catering to diverse patient needs in South Korea. Overall, collaboration amongst major players continues to fuel advancements in this vital sector.
Report Scope
Report Scope:
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 2.18(USD Billion) |
| MARKET SIZE 2024 | 2.24(USD Billion) |
| MARKET SIZE 2035 | 3.0(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 2.687% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Celltrion, CJ HealthCare, Medytox, Solco Healthcare, Hanmi Pharmaceutical, Korea United Pharm, DongA ST, Hannong Pharmaceutical, LG Chem, Kwangdong Pharmaceutical, Hugel, Daewoong Pharmaceutical, SK Chemicals, Yuhan Corporation, Samsung Biologics |
| SEGMENTS COVERED | Drug Class, Administration Route, Indication, Distribution Channel |
| KEY MARKET OPPORTUNITIES | Aging population increasing medication demand, Growing prevalence of hypertension cases, Rising healthcare expenditure and access, Advancements in drug formulations, Increased focus on preventive care solutions |
| KEY MARKET DYNAMICS | aging population, increasing prevalence of hypertension, government healthcare policies, rising healthcare expenditure, innovative drug formulations |
| COUNTRIES COVERED | South Korea |
FAQs
What is the expected market size of the South Korea Antihypertensive Drugs Market in 2024?
The South Korea Antihypertensive Drugs Market is expected to be valued at 2.24 billion USD in 2024.
What will be the market size of the South Korea Antihypertensive Drugs Market by 2035?
By 2035, the market size is projected to reach 3.0 billion USD.
What is the anticipated compound annual growth rate (CAGR) for the South Korea Antihypertensive Drugs Market from 2025 to 2035?
The anticipated CAGR for the South Korea Antihypertensive Drugs Market from 2025 to 2035 is 2.687%.
Which drug class will dominate the South Korea Antihypertensive Drugs Market by 2035?
By 2035, Diuretics will dominate the market, projected to reach 0.8 billion USD.
What is the market value for ACE Inhibitors in the South Korea Antihypertensive Drugs Market in 2024?
In 2024, the market value for ACE Inhibitors is expected to be 0.48 billion USD.
Which major players are competing in the South Korea Antihypertensive Drugs Market?
Major players include Celltrion, CJ HealthCare, Medytox, and Hanmi Pharmaceutical among others.
What is the market size for Beta Blockers in the South Korea Antihypertensive Drugs Market by 2035?
The market size for Beta Blockers is expected to reach 0.6 billion USD by 2035.
How does the current market growth rate compare for different drug classes in South Korea?
The growth rate varies, with Diuretics and ACE Inhibitors leading in market expansion within the forecast period.
What are the projected revenues for Calcium Channel Blockers in the South Korea Antihypertensive Drugs Market by 2035?
Projected revenues for Calcium Channel Blockers are expected to reach 0.5 billion USD by 2035.
What market trends are influencing the South Korea Antihypertensive Drugs Market's growth?
Emerging trends include advancements in drug formulations and increasing awareness of hypertension management.
Download Free Sample
Kindly complete the form below to receive a free sample of this Report
Customer Stories
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
Noah Malgeri
Co-Founder
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
Joseph Aguayo
Sales Operations & Pricing Manager
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
Peter Groot koerkamp
Account and Business Manager
“Thank you, this will be very helpful for OQS.”
La Terria Dodd
Program Support Specialist
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
Younghwan Choi
Senior Retail Manager
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Mark Irwin
Management Consultant
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
Akif Moroglu
Strategy & Business Development Director
Case Study
Aerospace & Defense
Leave a Comment